Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids (NOOA)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01027143 |
Recruitment Status :
Completed
First Posted : December 7, 2009
Last Update Posted : February 13, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Asthma Obesity | Dietary Supplement: omega-3 polyunsaturated fatty acids Drug: Omega-3 Fatty Acid | Phase 2 Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 144 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Obesity & Asthma: Nutrigenetic Response to Omega-3 Fatty Acids |
Study Start Date : | July 2010 |
Actual Primary Completion Date : | October 22, 2016 |
Actual Study Completion Date : | October 22, 2016 |
Arm | Intervention/treatment |
---|---|
Experimental: omega-3 fatty acids
3 softgels (EPA, DHA) twice daily
|
Dietary Supplement: omega-3 polyunsaturated fatty acids
ProEPA Xtra 1000mg softgels: 3 softgels twice daily
Other Name: ProEPA Xtra 1000mg softgels |
Placebo Comparator: control
Soybean oil: 3 matched softgel caps twice daily
|
Drug: Omega-3 Fatty Acid
Soybean oil: 3(age 12-25) matched softgel caps twice daily
Other Name: Placebo Soybean oil 1000mg soft gels |
- Asthma Control Questionnaire (Juniper) [ Time Frame: baseline, 12 weeks, 24 weeks ]
- Asthma symptom exacerbation, plasma membrane PUFA composition, spirometry, peak flow, forced oscillation [ Time Frame: baseline, 12 weeks, 24 weeks ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years to 25 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- age 12-25
- BMI > 25 (age 18-25) or BMI%>85th (age 12-17) (BMI Liberalized)
- Physician diagnosis of persistent asthma
- Lung function responsiveness by bronchodilator reversibility or bronchoprovocation testing
Exclusion Criteria:
- pregnancy
- currently taking LTRA for asthma control
- other serious chronic medical condition
- bleeding diathesis
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01027143
United States, Florida | |
Nemours Children's Clinic | |
Jacksonville, Florida, United States, 32207 | |
Nemours Children's Hospital/Dept of Pulmonology | |
Orlando, Florida, United States, 32827 | |
University of South Florida, Morsani College of Medicine | |
Tampa, Florida, United States, 33612 |
Principal Investigator: | Jason E. Lang, M.D. | Duke Children's Hospital and Health Center |
Responsible Party: | Nemours Children's Clinic |
ClinicalTrials.gov Identifier: | NCT01027143 History of Changes |
Other Study ID Numbers: |
NCCJELK23 |
First Posted: | December 7, 2009 Key Record Dates |
Last Update Posted: | February 13, 2017 |
Last Verified: | March 2016 |
Keywords provided by Nemours Children's Clinic:
Asthma Obesity Pharmacogenetics Nutrigenetics |
Additional relevant MeSH terms:
Obesity Asthma Overnutrition Nutrition Disorders Overweight Body Weight Signs and Symptoms Bronchial Diseases |
Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases |